ABBVIE INC (1ABBV.MI) Stock Price & Overview
BIT:1ABBV • US00287Y1091
Current stock price
The current stock price of 1ABBV.MI is 185.2 EUR. Today 1ABBV.MI is up by 0.11%. In the past month the price increased by 0.33%.
1ABBV.MI Key Statistics
- Market Cap
- 327.319B
- P/E
- 21.84
- Fwd P/E
- 15.04
- EPS (TTM)
- 8.48
- Dividend Yield
- 3.16%
1ABBV.MI Stock Performance
1ABBV.MI Stock Chart
1ABBV.MI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to 1ABBV.MI.
1ABBV.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1ABBV.MI. 1ABBV.MI has a medium profitability rating, but doesn't score so well on its financial health evaluation.
1ABBV.MI Earnings
On February 4, 2026 1ABBV.MI reported an EPS of 2.71 and a revenue of 16.62B. The company beat EPS expectations (0.18% surprise) and missed revenue expectations (-0.78% surprise).
1ABBV.MI Forecast & Estimates
37 analysts have analysed 1ABBV.MI and the average price target is 214.66 EUR. This implies a price increase of 15.91% is expected in the next year compared to the current price of 185.2.
For the next year, analysts expect an EPS growth of 45.22% and a revenue growth 9.84% for 1ABBV.MI
1ABBV.MI Groups
Sector & Classification
1ABBV.MI Financial Highlights
Over the last trailing twelve months 1ABBV.MI reported a non-GAAP Earnings per Share(EPS) of 8.48. The EPS decreased by -1.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.94% | ||
| ROA | 1.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
1ABBV.MI Ownership
1ABBV.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 25.34 | 38.133B | ||
| ARGX | ARGENX SE | 25.4 | 38.12B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.515B | ||
| ABVX | ABIVAX SA | N/A | 8.129B | ||
| 2X1 | ABIVAX SA | N/A | 8.097B | ||
| GXE | GALAPAGOS NV | N/A | 1.831B | ||
| GLPG | GALAPAGOS NV | N/A | 1.827B | ||
| NANO | NANOBIOTIX | N/A | 1.328B | ||
| IVA | INVENTIVA SA | N/A | 1.098B | ||
| 6IV | INVENTIVA SA | N/A | 1.098B | ||
| PHIL | PHILOGEN SPA | 18.09 | 663.748M | ||
| XUP | GENFIT | N/A | 468.027M | ||
| GNFT | GENFIT | 832.35 | 435.275M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1ABBV.MI
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Company Info
IPO: 2013-01-02
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS US
Employees: 55000
Phone: 18479327900
ABBVIE INC / 1ABBV.MI FAQ
Can you describe the business of ABBVIE INC?
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
What is the stock price of ABBVIE INC today?
The current stock price of 1ABBV.MI is 185.2 EUR. The price increased by 0.11% in the last trading session.
Does 1ABBV stock pay dividends?
ABBVIE INC (1ABBV.MI) has a dividend yield of 3.16%. The yearly dividend amount is currently 5.29.
How is the ChartMill rating for ABBVIE INC?
1ABBV.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the PE ratio for 1ABBV stock?
The PE ratio for ABBVIE INC (1ABBV.MI) is 21.84. This is based on the reported non-GAAP earnings per share of 8.48 and the current share price of 185.2 EUR.
When does ABBVIE INC (1ABBV.MI) report earnings?
ABBVIE INC (1ABBV.MI) will report earnings on 2026-04-23, before the market open.
Can you provide the ownership details for 1ABBV stock?
You can find the ownership structure of ABBVIE INC (1ABBV.MI) on the Ownership tab.